Myasthenic

Myasthenic is an adjective used in medicine to describe things related to myasthenia, particularly myasthenia gravis, a chronic autoimmune neuromuscular disorder characterized by fluctuating muscle weakness that worsens with activity and improves with rest. The term derives from Greek roots meaning muscle weakness.

In clinical use, myasthenic describes patients who have fatigable weakness due to impaired transmission at the neuromuscular junction. Common manifestations include ptosis, diplopia, facial weakness, dysarthria, dysphagia, and proximal limb weakness. Symptoms typically worsen with sustained use and may improve after rest or sleep.

The underlying cause is an autoimmune attack on components of the neuromuscular junction, most commonly antibodies against the acetylcholine receptor or muscle-specific kinase, often with thymic abnormalities such as thymic hyperplasia or thymoma. A subset of patients may be seronegative for these antibodies.

Diagnosis involves testing for antibodies (AChR, MuSK) and evaluating neuromuscular transmission with electrophysiology, such as repetitive nerve stimulation or single-fiber EMG. The ice pack test can aid in assessment, and chest imaging may reveal thymic abnormalities.

Treatment aims to improve transmission and modulate the immune response. Options include acetylcholinesterase inhibitors (pyridostigmine) for symptomatic relief, corticosteroids, and other immunosuppressants; thymectomy is considered in appropriate thymic pathology; rapid therapies like intravenous immunoglobulin or plasmapheresis are used in crisis or severe episodes. Prognosis varies, but many patients achieve good control with therapy and can lead near-normal lives; however, a myasthenic crisis, involving respiratory failure, remains a potential life-threatening event. MG affects about 20 per 100,000 people, with bimodal onset across age groups.